{"organizations": [], "uuid": "4bc366a1ca8b977af254656d903b660542203dea", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-sinovac-announces-preliminary-resu/brief-sinovac-announces-preliminary-results-of-phase-iii-trial-on-sipv-idUSASC09WIL", "country": "US", "domain_rank": 408, "title": "BRIEF-Sinovac Announces Preliminary Results Of Phase Iii Trial On Sipv", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-19T16:19:00.000+03:00", "replies_count": 0, "uuid": "4bc366a1ca8b977af254656d903b660542203dea"}, "author": "", "url": "https://www.reuters.com/article/brief-sinovac-announces-preliminary-resu/brief-sinovac-announces-preliminary-results-of-phase-iii-trial-on-sipv-idUSASC09WIL", "ord_in_thread": 0, "title": "BRIEF-Sinovac Announces Preliminary Results Of Phase Iii Trial On Sipv", "locations": [], "entities": {"persons": [{"name": "pha", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "brief-sinovac", "sentiment": "negative"}, {"name": "sipv reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "sinovac biotech ltd", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 19, 2018 / 1:22 PM / Updated 21 minutes ago BRIEF-Sinovac Announces Preliminary Results Of Phase Iii Trial On Sipv Reuters Staff \nApril 19 (Reuters) - Sinovac Biotech Ltd: \n* SINOVAC ANNOUNCES PRELIMINARY RESULTS OF PHASE III TRIAL ON SIPV \n* SINOVAC BIOTECH - PRELIM RESULTS OF TRIAL AFTER UNBLINDING SHOW SEROCONVERSION RATE OF POLIOVIRUS TYPE II IS SUPERIOR TO CONTROL VACCINE Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-19T16:19:00.000+03:00", "crawled": "2018-04-19T16:49:26.000+03:00", "highlightTitle": ""}